<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814316</url>
  </required_header>
  <id_info>
    <org_study_id>B.30.2.ATA.0.01.00/500</org_study_id>
    <nct_id>NCT04814316</nct_id>
  </id_info>
  <brief_title>Effects of Lansoprazole on Bone Turnover Markers</brief_title>
  <official_title>Evaluation of the Effects of Lansoprazole Usage on Bone Turnover Markers in Children With Gastroesophageal Reflux or Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of proton pump inhibitors (PPI) has increased in recent years. There are concerns that&#xD;
      PPIs have possible negative effects on bone metabolism. It has been suggested that PPIs may&#xD;
      reduce the absorption of calcium from the small intestine and lead to bone resorption by&#xD;
      affecting osteoclastic activity. In this study, it is planned to investigate the effects of&#xD;
      lansoprazole, a proton pump inhibitor, on bone turnover markers in pediatric patients with&#xD;
      gastroesophageal reflux or gastroesophageal reflux disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is planned to be conducted with children who are diagnosed with gastroesophageal&#xD;
      reflux or gastroesophageal reflux disease aged 2-18 years and healthy volunteers. The&#xD;
      diagnosis of gastroesophageal reflux will be made in accordance with the guidelines of North&#xD;
      American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and&#xD;
      European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). Written&#xD;
      and verbal consent will be obtained from patients/healthy volunteers and/or parents who want&#xD;
      to participate in the study. Serum calcium, magnesium, alkaline phosphatase, parathormone,&#xD;
      25-OH vitamin D and osteocalcin and urine calcium, creatinine, deoxypyridinoline, C-terminal&#xD;
      telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen levels will be&#xD;
      measured at baseline and second month in study group and once in control groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measuring serum calcium levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum calcium levels with spectrophotometric method (mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring serum alkaline phosphatase levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum alkaline phosphatase levels with spectrophotometric method (U/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring serum magnesium levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum magnesium levels with spectrophotometric method (mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring serum osteocalcin levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum osteocalcin levels with spectrophotometric method (mg/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring serum parathyroid hormone levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum parathyroid hormone levels with immunoassay method (pg/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring serum vitamin D levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring serum vitamin D with immunoassay method (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring urine deoxypyridinoline levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring urine deoxypyridinoline levels with immunoassay method (nmol DPD/mmol creatinine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring spot urine calcium levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring urine calcium levels with spectrophotometric method (mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring urine creatinine levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring urine creatinine levels with spectrophotometric method (mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring urine C-terminal telopeptides Type I collagen levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring urine C-terminal telopeptides Type I collagen levels with immunoassay method (ng/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring urine N-terminal telopeptides Type I collagen levels</measure>
    <time_frame>First day</time_frame>
    <description>Measuring urine N-terminal telopeptides Type I collagen levels with immunoassay method (ng/mL).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Bone Turnover Rate Disorder</condition>
  <condition>Calcium Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients with gastroesophageal reflux or gastroesophageal reflux disease who will use lansoprazole.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Healty volunteers who will not use lansoprazole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood and urine specimens</intervention_name>
    <description>Blood and urine samples will be taken at baseline and at the end of the second month for study group and only at baseline for control group.&#xD;
For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      5ml EDTA blood and 3 ml urine specimens will be collected for each case.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with gastroesophageal reflux or gastroesophageal reflux disease aged 2 to18 years&#xD;
        who were treated in Pediatric Gastroenterology Department of Ataturk University Hospital&#xD;
        included to the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Patients diagnosed with gastroesophageal reflux or gastroesophageal reflux disease aged&#xD;
        16 to18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a malabsorptive disease.&#xD;
&#xD;
          -  Patients with any chronic disease.&#xD;
&#xD;
          -  Patients who use any medication that may affect calcium and bone metabolism.&#xD;
&#xD;
          -  Patients who used proton pumps inhibitor within the last 3 months.&#xD;
&#xD;
          -  Patients who do not use lansoprazole in the study group.&#xD;
&#xD;
          -  Patients whose blood and urine samples are not taken in the eighth week of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali Islek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ataturk University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ataturk University Hospital</name>
      <address>
        <city>Erzurum</city>
        <zip>25240</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Sheraly AR, Lickorish D, Sarraf F, Davies JE. Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv. 2009 Apr;6(2):192-8.</citation>
    <PMID>19450226</PMID>
  </results_reference>
  <results_reference>
    <citation>Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008 Aug 12;179(4):319-26. doi: 10.1503/cmaj.071330.</citation>
    <PMID>18695179</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53.</citation>
    <PMID>17190895</PMID>
  </results_reference>
  <results_reference>
    <citation>Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010 Mar;138(3):896-904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.</citation>
    <PMID>19931262</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharara AI, El-Halabi MM, Ghaith OA, Habib RH, Mansour NM, Malli A, El Hajj-Fuleihan G. Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study. Metabolism. 2013 Apr;62(4):518-26. doi: 10.1016/j.metabol.2012.09.011. Epub 2012 Oct 24.</citation>
    <PMID>23102518</PMID>
  </results_reference>
  <results_reference>
    <citation>Kocsis I, Arató A, Bodánszky H, Szönyi L, Szabó A, Tulassay T, Vásárhelyi B. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int. 2002 Aug;71(2):129-32. Epub 2002 Jul 23.</citation>
    <PMID>12200646</PMID>
  </results_reference>
  <results_reference>
    <citation>Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002 Jul;31(1):57-61.</citation>
    <PMID>12110413</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Ali Islek</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Lansoprazole</keyword>
  <keyword>Bone turnover</keyword>
  <keyword>Gastroesophageal reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Calcium Metabolism Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

